Current standards and new trends in the primary treatment of colorectal cancer
References (10)
- et al.
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
J Clin Oncol
(2010) - et al.
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer
J Clin Oncol
(2011) - et al.
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
J Clin Oncol
(2011) - et al.
Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors
J Clin Oncol
(2010) - et al.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
J Clin Oncol
(2008)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2011 Elsevier Ltd. All rights reserved.